These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36698747)

  • 21. Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't.
    Ong ACM; Torra R
    Clin Kidney J; 2022 Jun; 15(6):1034-1036. PubMed ID: 35664267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Jeremiah Metzger Lecture. Polycystic kidney disease: old disease in a new context.
    Grantham JJ
    Trans Am Clin Climatol Assoc; 2002; 113():211-24; discussion 224-6. PubMed ID: 12053711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Autosomal Dominant Polycystic Kidney Disease.
    Jdiaa SS; Mustafa RA; Yu ASL
    Am J Kidney Dis; 2024 Oct; ():. PubMed ID: 39424253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical practice guidelines for polycystic kidney diseases].
    Writing Group For Practice Guidelines For Diagnosis And Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese Medical Association ; Xu D; Mei C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Mar; 37(3):277-283. PubMed ID: 32128744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.
    Rizk D; Chapman A
    Pediatr Nephrol; 2008 Jul; 23(7):1029-36. PubMed ID: 18259779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in Autosomal Dominant Polycystic Kidney Disease: A Clinical Review.
    Nobakht N; Hanna RM; Al-Baghdadi M; Ameen KM; Arman F; Nobahkt E; Kamgar M; Rastogi A
    Kidney Med; 2020; 2(2):196-208. PubMed ID: 32734239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
    Chapman AB
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging Therapies for Childhood Polycystic Kidney Disease.
    Sweeney WE; Avner ED
    Front Pediatr; 2017; 5():77. PubMed ID: 28473970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases.
    Vasileva VY; Sultanova RF; Sudarikova AV; Ilatovskaya DV
    Front Physiol; 2021; 12():693130. PubMed ID: 34566674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective.
    Kanhai AA; Bange H; Verburg L; Dijkstra KL; Price LS; Peters DJM; Leonhard WN
    Sci Rep; 2020 Feb; 10(1):1672. PubMed ID: 32015419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Tangri N; Hougen I; Alam A; Perrone R; McFarlane P; Pei Y
    Can J Kidney Health Dis; 2017; 4():2054358117693355. PubMed ID: 28321323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells.
    Asawa RR; Danchik C; Zakharov A; Chen Y; Voss T; Jadhav A; Wallace DP; Trott JF; Weiss RH; Simeonov A; Martinez NJ
    Sci Rep; 2020 Mar; 10(1):4203. PubMed ID: 32144367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular genetic analysis of polycystic kidney disease 1 and polycystic kidney disease 2 mutations in pedigrees with autosomal dominant polycystic kidney disease.
    Bitarafan F; Garshasbi M
    J Res Med Sci; 2019; 24():44. PubMed ID: 31160911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Research progress in autosomal dominant polycystic kidney disease].
    Hu S; Li D; Tan X; Gu J; Chen M; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.